Hemogenix Inc

HemoGenix Inc is a privately-held, Colorado-based contract research service and assay development company. It has developed standardized and validated assays for in vitro toxicity testing of various primary cell systems, with a focus on stem cell hemotoxicity testing. The company also offers services and assays for immunotoxicity, hepatotoxicity, and cardiotoxicity. HemoGenix's patent and proprietary assay portfolio includes assays for basic and veterinary research, as well as cell therapy assays for cord blood banking, stem cell transplantation, and regenerative medicine applications. The company advocates for the use of "Best Practices" to measure umbilical cord blood stem cell quality and potency to reduce graft failure rates. HemoGenix specializes in contract services and assays for toxicity testing, stem cell research, and stem cell therapeutic quality and potency testing. The company's HALO Kit Platform, with over 360 different kit variations and multiple formats, was developed to meet the need for a rapid, nonsubjective, and standardized stem cell hemotoxicity detection system with high-throughput capability. Founded in March 2000, HemoGenix relocated to Colorado Springs, Colo., in 2003 to expand its operations and begin production of the HALO Kit Platform.